# Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer

> **NCT03377387** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 34 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Neratinib
- **BEHAVIORAL:** EORTC QLQ - BR23, EQ-5D-5L, EORTC QLQ-C30

## Key facts

- **NCT ID:** NCT03377387
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-12-13
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2026-04-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03377387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03377387, "Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03377387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*